Aquestive Therapeutics, Inc. (NASDAQ:AQST – Get Free Report) was the target of a significant growth in short interest during the month of July. As of July 15th, there was short interest totalling 10,370,000 shares, a growth of 35.9% from the June 30th total of 7,630,000 shares. Based on an average daily volume of 1,700,000 shares, the short-interest ratio is currently 6.1 days.
Aquestive Therapeutics Trading Up 10.7 %
Shares of AQST opened at $3.82 on Monday. The business’s 50 day moving average is $2.83 and its 200 day moving average is $3.31. The company has a market capitalization of $347.77 million, a PE ratio of -9.10 and a beta of 2.80. Aquestive Therapeutics has a 12-month low of $1.25 and a 12-month high of $6.23.
Aquestive Therapeutics (NASDAQ:AQST – Get Free Report) last issued its earnings results on Monday, May 13th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.08). The company had revenue of $12.05 million during the quarter, compared to the consensus estimate of $12.22 million. During the same quarter in the previous year, the business earned $0.11 earnings per share. Equities research analysts predict that Aquestive Therapeutics will post -0.49 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Read Our Latest Report on Aquestive Therapeutics
Institutional Trading of Aquestive Therapeutics
Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. SG Americas Securities LLC bought a new stake in Aquestive Therapeutics in the 1st quarter worth approximately $54,000. Lazard Asset Management LLC increased its stake in Aquestive Therapeutics by 115.5% in the 1st quarter. Lazard Asset Management LLC now owns 29,112 shares of the company’s stock worth $124,000 after acquiring an additional 15,601 shares during the last quarter. Jump Financial LLC bought a new stake in Aquestive Therapeutics in the 4th quarter worth approximately $60,000. PFG Investments LLC bought a new stake in Aquestive Therapeutics in the 1st quarter worth approximately $204,000. Finally, Virtu Financial LLC increased its stake in Aquestive Therapeutics by 219.7% in the 1st quarter. Virtu Financial LLC now owns 102,836 shares of the company’s stock worth $438,000 after acquiring an additional 70,666 shares during the last quarter. Institutional investors own 32.45% of the company’s stock.
Aquestive Therapeutics Company Profile
Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.
Further Reading
- Five stocks we like better than Aquestive Therapeutics
- Trading Stocks: RSI and Why it’s Useful
- Is Crypto Cool Again? What Stocks You Should Be Watching
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Why Call Options Volume for These 2 Stocks Spiked Together
- The How And Why of Investing in Oil Stocks
- MarketBeat Week in Review – 7/22 – 7/26
Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.